Marc Beer is the co-founder of a Boston based med-tech Startup Company by the name Revonia Inc. the company is basically working towards the development of different diagnostic and therapeutic products used for treatment of disorders such as urinary incontinence. According to an estimate done by researchers, the urinary incontinence disorder affects over 250 million women in the entire world. The approval of the company’s first product by the FDA back in April was a major improvement.
Marc Beer also is the founder and the Chief Executive Officer of the ViaCell which is a biotechnology company that specializes in the collection, preservation and development of stem cells of the umbilical cord. Marc Beer led the company for seven years after its establishment, helping it to develop into a successful and enviable commercial organization. As an indicator of good leadership by Marc Beer, the company was able to go public back in the year 2005 and employing more than three hundred people.
Marc Beer has held other different leadership position in different organizations such as the board member of the Erytech Pharma, chairman of the board of directors of the Good Start Genetics, Inc. and member of the Business Advisory Miami University just to mention a few. Marc Beer is an alumnus of the Miami University in Ohio.
Longwood Fund which is an investing firm focusing on healthcare oriented companies has already invested in Revonia. Their funding to the company will be used to develop more diagnostic and therapeutic products, with the new generation of Leva Device not left out. According to Marc Beer, the support from Longwood firm to help the people affected by the pelvic floor disorders is something they are all happy about as the entire company. He also added that with the kind of knowledge and experience in their work, they will be in a better position to educate people on the pelvic floor disorders and also inform on the better treatment options.
In five years’ time after Marc Beer co-founded the Renovia Inc. the company was able to develop a drug called Juxtapid. However, the FDA later on accused him for suggesting that the drug was effective when it comes to the treatment of conditions related to the heart. Marc Beer has also held several roles concerning sales and marketing, he has an experience of over 25 years in development of biotechnology, diagnostic industries, devices and pharmaceutical. Learn more: https://www1.salary.com/Marc-Beer-Salary-Bonus-Stock-Options-for-AEGERION-PHARMACEUTICALS-INC.html
Leave a Reply
You must be logged in to post a comment.